Anvesh Dasari

Rani Therapeutics (United States)

Papers

4

Total Citations

101

H-Index

2

About

Anvesh Dasari is a pioneering biomedical researcher at the forefront of oral drug delivery, specializing in the development of robotic pills to transform the administration of biotherapeutics. His major contributions center on engineering ingestible devices that can safely and reliably deliver large-molecule drugs—such as teriparatide for osteoporosis—directly into the gastrointestinal tract, bypassing the need for painful injections. Dasari’s landmark 2021 study, cited 94 times, demonstrated the safety, tolerability, and performance of a robotic pill in healthy subjects, addressing a critical barrier in patient compliance for chronic diseases. His subsequent phase 1 trials, including a 2025 study with high bioavailability results, have further validated this technology’s clinical potential, achieving over 100 cumulative citations. Notably, Dasari’s work at Rani Therapeutics has advanced the field by showing that oral delivery of osteoanabolic agents can match injection efficacy while improving patient quality of life. His research holds promise for revolutionizing treatment adherence in osteoporosis and beyond, marking him as a key innovator in biomedical engineering and translational medicine.

Research Focus

Key Achievements

2
H-Index
4
Papers
101
Total Citations
25
Avg Citations/Paper
🏆 Most Cited Paper
A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects
94 citations · 2021
📈 Most Prolific Year: 2023 (2 Papers)
🤝 Key Collaborators: 38
🏛 Institutions: Rani Therapeutics (United States)

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago